Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Holding DNLI?
Track your performance easily
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.56 - $32.13
Previous Close$30.76
Volume1.22M
Average Volume (3M)1.11M
Market Cap
$4.40B
Enterprise Value$3.56B
Total Cash (Recent Filing)$896.04M
Total Debt (Recent Filing)$48.75M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Oct 31, 2024EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding143,165,264
10 Day Avg. Volume1,168,681
30 Day Avg. Volume1,109,414
Standard Deviation0.18
R-Squared0.16
Alpha0.00317
Financial Highlights & Ratios
Price to Book (P/B)3.02
Price to Sales (P/S)14.87
Price to Cash Flow (P/CF)-9.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.80
Enterprise Value/Gross Profit10.76
Enterprise Value/Ebitda23.28
Forecast
1Y Price Target
$39.50Price Target Upside28.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Denali Therapeutics News
Bulls Say, Bears Say
Bulls Say
Accelerated ApprovalThe FDA’s CDER division has opened a path for accelerated approval for tividenofusp alfa for the treatment of MPS II, potentially launching it ~2 years earlier than traditional approval.
Clinical DataDNL310 has shown significant reductions in cerebrospinal fluid heparan sulfate levels, normalizing in 100% of participants by week 24, suggesting strong clinical efficacy.
Regulatory AlignmentDenali and the FDA have reached alignment on a registrational path that includes early 2025 BLA submission under the accelerated approval pathway for DNL310.
Bears Say
LicensingBiogen terminated its license to the ATV:Abeta program.
Price TargetThe price target has been reduced from $95 to $90.
Stock PerformanceDNLI shares sold off by approximately 4% after news of Biogen’s termination of ATV:Abeta collaboration for Alzheimer’s.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $32.13 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Aug 01, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.686 by $0.096.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -$0.62.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 143,165,270 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.686. Following the earnings report the stock price went down -4.268%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Baker Bros Advisors LP. It holds Denali Therapeutics’s shares valued at 87M.
---
Denali Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (28.41% Upside)
$39.50 (28.41% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $332.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.99%
12-Months-Change
Fundamentals
Return on Equity
-32.61%
Trailing 12-Months
Asset Growth
15.07%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$39.50
▲(28.41% Upside)
Technical Analysis
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+52.48%
reiterated a buy rating 17 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.48% per trade.
---